Experimental drug losmapimod tested for rare muscle disease

NCT ID NCT04264442

Terminated Disease control Sponsor: Fulcrum Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested the drug losmapimod in 76 adults with FSHD, a genetic condition that causes progressive muscle weakness. Participants took either losmapimod or a placebo for 48 weeks to see if the drug was safe and could help control the disease. The study was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Losmapimod (a drug taken as a pill twice daily)
What this could lead to: If it works, this could point toward a treatment that slows or controls muscle weakness in people with FSHD.
What could go wrong: This trial was terminated early, so results are limited. It is a small, phase 2 study, and the drug may not prove effective or safe in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

facioscapulohumeral muscular dystrophy facioscapulohumeral muscular dystrophy 1 muscular dystrophy musculoskeletal system disorder neuromuscular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)

Contacts and locations

Locations

CHU de NICE- CHU pasteur2

Nice, 06001, France
Hospital UiP La Fe

Valencia, 46026, Spain
Hospital de la Sta Creu i St Pau

Barcelona, 08041, Spain
Kennedy Krieger Institute

Baltimore, Maryland, 21205, United States
Montreal Neurological Institute and Hospital

Montreal, Quebec, H3A 2B4, Canada
Ohio State University

Columbus, Ohio, 43221, United States
Ottawa Hospital Research Institute

Ottawa, Ontario, K1Y 4E9, Canada
University of California Irvine

Irvine, California, 92868, United States
University of California Los Angeles (UCLA)

Los Angeles, California, 90095, United States
University of Florida

Gainesville, Florida, 32610, United States
University of Kansas Medical Center

Kansas City, Kansas, 66160, United States
University of Massachusetts Memorial Medical Center

Worcester, Massachusetts, 01655, United States
University of Rochester Medical Center

Rochester, New York, 14642, United States
University of Utah

Salt Lake City, Utah, 84132, United States
University of Washinton Medical Center

Seattle, Washington, 98195, United States
Virginia Commonwealth University

Richmond, Virginia, 23298, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.